A detailed history of Blueprint Investment Partners LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Blueprint Investment Partners LLC holds 4,778 shares of ABBV stock, worth $962,767. This represents 0.2% of its overall portfolio holdings.

Number of Shares
4,778
Previous 7,105 32.75%
Holding current value
$962,767
Previous $1.29 Million 36.66%
% of portfolio
0.2%
Previous 0.35%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $360,196 - $420,628
-2,327 Reduced 32.75%
4,778 $819,000
Q1 2024

May 13, 2024

BUY
$159.82 - $182.1 $458,363 - $522,262
2,868 Added 67.69%
7,105 $1.29 Million
Q4 2023

Feb 13, 2024

BUY
$137.6 - $154.97 $223,049 - $251,206
1,621 Added 61.96%
4,237 $656,000
Q3 2023

Nov 15, 2023

BUY
$133.59 - $154.65 $349,471 - $404,564
2,616 New
2,616 $389,000
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $956,016 - $1.1 Million
-6,611 Reduced 59.61%
4,479 $713,000
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $691,135 - $828,852
4,997 Added 82.01%
11,090 $1.79 Million
Q3 2022

Nov 09, 2022

SELL
$134.21 - $153.93 $290,698 - $333,412
-2,166 Reduced 26.23%
6,093 $818,000
Q2 2022

Aug 09, 2022

BUY
$137.62 - $174.96 $384,372 - $488,663
2,793 Added 51.1%
8,259 $1.27 Million
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $91,198 - $113,151
691 Added 14.47%
5,466 $886,000
Q4 2021

Feb 15, 2022

BUY
$107.43 - $135.93 $168,127 - $212,730
1,565 Added 48.75%
4,775 $646,000
Q3 2021

Nov 04, 2021

BUY
$106.4 - $120.78 $341,544 - $387,703
3,210 New
3,210 $346,000
Q2 2021

Aug 09, 2021

SELL
$105.21 - $117.21 $204,528 - $227,856
-1,944 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $198,871 - $218,933
1,944 New
1,944 $210,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $356B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Blueprint Investment Partners LLC Portfolio

Follow Blueprint Investment Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blueprint Investment Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Blueprint Investment Partners LLC with notifications on news.